ReviewKorean circulation journal2025
Twenty-Year Clinical Experience of the Korea Acute Myocardial Infarction Registry.
Review in Korean circulation journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Relationship Between the "Life's Essential 8" Lifestyle Metrics and Serum High-Sensitivity C-Reactive Protein Levels in South Korea.Life (Basel, Switzerland) · 2026Article
- Overview of methodology and characteristics of national acute coronary syndrome registries in high-income countries: a scoping review.European heart journal open · 2026Review
- Clinical profile and short-term outcomes of acute myocardial infarction patients.Bioinformation · 2026Article
- Clinical, Laboratory and Instrumental Characteristics of Myocardial Infarction in Young Patients Depending on the Prevalence of Coronary Atherosclerosis.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Korea Acute Myocardial Infarction Registry (KAMIR) was established in 2005 to address the paucity of large-scale, real-world evidence on acute myocardial infarction (AMI) in East Asia. Over the last 2 decades, KAMIR has enrolled more than 86,000 patients across multiple centers in Korea, enabling comprehensive analyses of epidemiology, risk profiles, risk stratification, acute interventional management, and medical therapies. The registry has documented temporal shifts from ST-segment elevation myocardial infarction to non-ST-segment elevation myocardial infarction, progressive population aging, and distinctive metabolic risk profiles characterized by a high prevalence of diabetes and low levels of high-density lipoprotein cholesterol. KAMIR has also supported the development and validation of prognostic tools, including the KAMIR risk score and artificial intelligence-driven models. Widespread adoption of primary percutaneous coronary intervention, advanced stent technologies, intravascular imaging, and tailored antithrombotic strategies have improved procedural success rates and reduced mortality. Long-term medical therapy findings underscore the importance of intensive lipid-lowering, optimized renin-angiotensin system blockade, and individualized antiplatelet regimens, with emerging evidence supporting sodium-glucose cotransporter 2 inhibitors. KAMIR evidence has informed national guidelines and holds strong potential to guide future East Asian consensus guidelines, highlighting the value of region-specific data in shaping global cardiovascular practice. Ongoing integration of precision medicine approaches, digital health tools, and multinational collaboration is expected to further advance AMI care in East Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.